Data reports
FDA novel drug approvals in 2026: the full list so far, with trends
Every FDA novel drug approval in 2026 so far: 53 new molecular entities and biologics through November 17, with dates, ingredients, approved uses and trends.
By the All In Biotech editorial team · Published November 18, 2026 · 7 min read
FDA's Center for Drug Evaluation and Research (CDER) approved 53 novel drugs between January 1 and November 17, 2026. That is already more than the full-year totals for 2021, 2022, 2024 and 2025, and two fewer than 2023. The full list is below, with dates, active ingredients and a short description of each approved use.
The figures come from this site's copy of FDA's Novel Drug Approvals pages, as of November 2026. FDA updates that list as approvals happen, so the count will change before the year ends.
What counts as a novel drug approval
A novel approval is a new molecular entity (NME) approved through a new drug application (NDA), or a new therapeutic biologic approved through a biologics license application (BLA), whose active ingredient has never been approved in the United States. CDER publishes one list per year.
Three points matter when reading the count:
- It covers CDER only. Most vaccines, blood products and cell and gene therapies are approved by FDA's Center for Biologics Evaluation and Research (CBER) and do not appear here.
- New uses for existing drugs, new formulations and new combinations of previously approved ingredients are not novel approvals. Those show up as efficacy supplements or other approvals on /approvals.
- A biosimilar is not a novel approval, even though it is a new BLA.
Year-over-year count
| Year | CDER novel approvals |
|---|---|
| 2021 | 50 |
| 2022 | 36 |
| 2023 | 55 |
| 2024 | 50 |
| 2025 | 46 |
| 2026 (through Nov 17) | 53 |
The 2026 figure is partial. Approvals in the last six weeks of a year can add several more names, so comparisons with full prior years are only provisional until FDA's list closes.
The full 2026 list so far
Uses are shortened from FDA's descriptions. Check the label for the exact approved indication, which often includes conditions on prior therapy, age or biomarker status.
| Date | Drug | Ingredient | Approved use |
|---|---|---|---|
| 2026-01-12 | Zycubo | copper histidinate | Menkes disease |
| 2026-02-12 | Adquey | difamilast | Mild to moderate atopic dermatitis |
| 2026-02-20 | Bysanti | milsaperidone | Schizophrenia and bipolar I manic or mixed episodes |
| 2026-02-23 | Loargys | pegzilarginase-nbln | Hyperarginemia in arginase 1 deficiency |
| 2026-02-27 | Yuviwel | navepegritide | Linear growth in children with achondroplasia |
| 2026-03-17 | Icotyde | icotrokinra | Moderate-to-severe plaque psoriasis |
| 2026-03-17 | Lynavoy | linerixibat | Cholestatic pruritus in primary biliary cholangitis |
| 2026-03-24 | Avlayah | tividenofusp alfa-eknm | Hunter syndrome (MPS II) |
| 2026-03-25 | Lifyorli | relacorilant | Platinum-resistant ovarian, fallopian tube or peritoneal cancer |
| 2026-03-26 | Awiqli | insulin icodec-abae | Glycemic control in type 2 diabetes |
| 2026-04-01 | Foundayo | orforglipron | Chronic weight management |
| 2026-04-20 | Idvynso | doravirine and islatravir | HIV-1 switch regimen in suppressed adults |
| 2026-05-01 | Veppanu | vepdegestrant | ER+/HER2- ESR1-mutated advanced breast cancer |
| 2026-05-13 | Beqalzi | sonrotoclax | Relapsed or refractory mantle cell lymphoma |
| 2026-05-15 | Baxfendy | baxdrostat | Hypertension, with other antihypertensives |
| 2026-05-22 | Hepcludex | bulevirtide-gmod | Chronic hepatitis delta |
| 2026-05-27 | Decnupaz | pivekimab sunirine-pvzy | Blastic plasmacytoid dendritic cell neoplasm |
| 2026-05-29 | Cypsedo | cipepofol | Induction of general anesthesia |
| 2026-05-29 | Xocova | ensitrelvir | COVID-19 post-exposure prophylaxis |
| 2026-05-29 | Zaynich | cefepime and zidebactam | Complicated urinary tract infections |
| 2026-06-12 | Ambelvist | gadoquatrane | MRI contrast for lesions with abnormal vascularity |
| 2026-06-17 | Utebzi | tebipenem pivoxil | Complicated urinary tract infections (oral) |
| 2026-06-26 | Lumvoa | veligrotug-vvze | Thyroid eye disease |
| 2026-07-07 | Trutakna | atacicept-vymj | Proteinuria in IgA nephropathy |
| 2026-07-14 | Revtorpyk | gedatolisib | HR+/HER2- advanced breast cancer without PIK3CA mutation |
| 2026-07-15 | Lipfendra | enlicitide decanoate | Lowering LDL cholesterol |
| 2026-07-22 | Jideytro | zidesamtinib | ROS1-positive NSCLC after a ROS1 inhibitor |
| 2026-07-24 | Simtriyo | centanafadine | ADHD |
| 2026-07-24 | Lytenava | bevacizumab-vikg | Wet age-related macular degeneration |
| 2026-08-05 | Orzeyful | oveporexton | Narcolepsy type 1 |
| 2026-08-13 | Zenbexus | iberdomide | Multiple myeloma after at least one prior line |
| 2026-08-13 | Tauklarify | florquinitau F 18 | Tau PET imaging in suspected Alzheimer disease |
| 2026-08-19 | Pasatru | garetosmab-grts | Fibrodysplasia ossificans progressiva |
| 2026-08-26 | Rasonque | daraxonrasib | Metastatic pancreatic cancer |
| 2026-08-27 | Lisraya | brepocitinib | Dermatomyositis |
| 2026-08-28 | Mimrylo | rusfertide | Erythrocytosis in polycythemia vera |
| 2026-09-03 | Zanvastro | zilganersen | Alexander disease |
| 2026-09-04 | Etcamah | camizestrant | HR+/HER2- breast cancer with ESR1 mutation |
| 2026-09-11 | Pixclara | floretyrosine F 18 | PET imaging of recurrent or progressive glioma |
| 2026-09-11 | Isembyld | apitegromab-mstn | Spinal muscular atrophy, with SMN2-targeted therapy |
| 2026-09-23 | Lyrfigtu | lirafugratinib | FGFR2-altered cholangiocarcinoma |
| 2026-09-23 | Onswik | insulin efsitora alfa-gobe | Glycemic control in type 2 diabetes |
| 2026-09-25 | Atebrioz | zilurgisertib | Fibrodysplasia ossificans progressiva |
| 2026-09-25 | Juvmo | tavapadon | Parkinson's disease |
| 2026-09-28 | Emcitate | tiratricol | Peripheral thyrotoxicosis in MCT8 deficiency |
| 2026-10-09 | Hovilpri | pritelivir | Refractory herpes simplex in immunocompromised adults |
| 2026-10-20 | Hibsago | bepirovirsen | Chronic hepatitis B, with antiviral therapy |
| 2026-11-09 | Sunharbo | asundexian | Stroke risk reduction after mild-to-moderate stroke or high-risk TIA |
| 2026-11-13 | Klygefa | gefurulimab-gaks | AChR antibody-positive generalized myasthenia gravis |
| 2026-11-13 | Pimjetmi | pimicotinib | Tenosynovial giant cell tumor |
| 2026-11-16 | Wilserdly | giredestrant | ER+/HER2- ESR1-mutated advanced breast cancer |
| 2026-11-17 | Lembaz | adrabetadex | Severe Niemann-Pick disease type C |
| 2026-11-17 | Nelkarmi | neladalkib | ALK-positive NSCLC after prior therapy |
Patterns in the 2026 data
These observations come only from the list above and from the designation flags in this site's data. They describe what has been approved, not why.
Timing across the year
Approvals were uneven by month: 1 in January, 4 in February, 5 in March, 2 in April, 8 in May, 3 in June, 6 in July, 7 in August, 9 in September, 2 in October and 6 in the first 17 days of November. Monthly counts depend on when individual review clocks end, so a busy or quiet month says little on its own. For how those target dates are set, see what is a PDUFA date.
Therapeutic mix
- Cancer: 13 of the 53 approvals treat a cancer or tumor, counting tenosynovial giant cell tumor. Four are for hormone receptor-positive, HER2-negative breast cancer, and three of those four are limited to tumors with an ESR1 mutation (Veppanu, Etcamah, Wilserdly). Two are for non-small cell lung cancer with a specific driver (ROS1 and ALK).
- Infectious disease: 7 approvals, covering HIV-1, hepatitis B, hepatitis delta, COVID-19 prophylaxis, herpes simplex and two for complicated urinary tract infections.
- Cardiometabolic: two once-weekly insulins for type 2 diabetes (Awiqli and Onswik), an oral weight-management drug (Foundayo), an add-on blood pressure drug (Baxfendy), an LDL cholesterol-lowering drug (Lipfendra) and a stroke-prevention drug (Sunharbo).
- Neurology and psychiatry: schizophrenia and bipolar I disorder, ADHD, narcolepsy type 1, Parkinson's disease, spinal muscular atrophy, Alexander disease and generalized myasthenia gravis.
- Diagnostic imaging agents: three, an MRI contrast agent and two PET tracers (tau imaging and glioma imaging).
- Rare genetic and metabolic diseases: several, including Menkes disease, arginase 1 deficiency, achondroplasia, Hunter syndrome, MCT8 deficiency and Niemann-Pick disease type C. Two separate drugs were approved for fibrodysplasia ossificans progressiva within about five weeks of each other.
Orphan, priority and biologic shares
Of the 48 approvals this site has matched to Drugs@FDA application records so far, 23 (about 48%) carry an orphan marking, 31 (about 65%) had priority review and 11 are BLAs. The other five approvals (three of them from the past week) had not yet been matched to a record in the Drugs@FDA download used for this report.
FDA's breakthrough therapy and accelerated approval lists, which this site tracks on /designations, currently run through June 30, 2026. To that date they include 6 breakthrough approvals and 5 accelerated approvals among 2026 novel drugs. Those numbers will rise when FDA updates the lists. Orphan status is explained in orphan drug designation explained, and the expedited programs are compared in breakthrough, fast track, accelerated approval and priority review.
How to research any drug on the list
Each novel approval links to a drug page on this site once the application appears in Drugs@FDA. A drug page brings together:
- the current label's approved uses and any boxed warning,
- the approval history with FDA's letters and label PDFs,
- registered trials from ClinicalTrials.gov,
- adverse event reports from FAERS,
- Medicare spending, once CMS data covers the drug (newly approved drugs will not appear in Medicare data for a year or more).
To see every drug for a disease, not just this year's, use the condition search. For example, breast cancer and non-small cell lung cancer list all brand-name drugs whose labels name those cancers.
Where the official list lives
FDA's Novel Drug Approvals page links to each year's table and to CDER's annual summary reports. Labels for each product are on DailyMed and in Drugs@FDA. For approvals of vaccines and cell and gene therapies, check CBER's pages on fda.gov.
Frequently asked questions
- How many novel drugs has FDA approved in 2026?
- FDA's Center for Drug Evaluation and Research (CDER) listed 53 novel drug approvals from January 1 through November 17, 2026.
- What counts as a novel drug approval?
- A novel approval is a drug or therapeutic biologic whose active ingredient has never been approved in the United States before, as listed on CDER's Novel Drug Approvals page.
- Are vaccines and gene therapies included in the count?
- No. CDER's list does not include most vaccines, blood products and cell and gene therapies, which are approved by FDA's Center for Biologics Evaluation and Research (CBER).
- What share of 2026 novel approvals are orphan drugs?
- Of the 48 approvals this site matched to Drugs@FDA records, 23 carry an orphan marking and 31 had priority review.
For information only, not medical, legal or investment advice. Facts about FDA and CMS programs are current as of the publication date; check the linked official source for changes.